As of 2024-12-15, the EV/EBITDA ratio of Marinus Pharmaceuticals Inc (MRNS) is -0.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRNS's latest enterprise value is 27.51 mil USD. MRNS's TTM EBITDA according to its financial statements is -121.83 mil USD. Dividing these 2 quantities gives us the above MRNS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 10.2x | 8.8x |
| Forward P/E multiples | 12.4x - 17.1x | 15.2x |
| Fair Price | (27.61) - (22.84) | (26.67) |
| Upside | -10605.1% - -8790.8% | -10248.2% |
| Date | EV/EBITDA |
| 2024-12-13 | -0.23 |
| 2024-12-12 | -0.23 |
| 2024-12-11 | -0.24 |
| 2024-12-10 | -0.23 |
| 2024-12-09 | -0.24 |
| 2024-12-06 | -0.24 |
| 2024-12-05 | -0.23 |
| 2024-12-04 | -0.24 |
| 2024-12-03 | -0.25 |
| 2024-12-02 | -0.26 |
| 2024-11-29 | -0.25 |
| 2024-11-27 | -0.25 |
| 2024-11-26 | -0.25 |
| 2024-11-25 | -0.25 |
| 2024-11-22 | -0.25 |
| 2024-11-21 | -0.25 |
| 2024-11-20 | -0.25 |
| 2024-11-19 | -0.25 |
| 2024-11-18 | -0.25 |
| 2024-11-15 | -0.24 |
| 2024-11-14 | -0.25 |
| 2024-11-13 | -0.24 |
| 2024-11-12 | -0.26 |
| 2024-11-11 | -0.26 |
| 2024-11-08 | -0.26 |
| 2024-11-07 | -0.27 |
| 2024-11-06 | -0.26 |
| 2024-11-05 | -0.25 |
| 2024-11-04 | -0.26 |
| 2024-11-01 | -0.26 |
| 2024-10-31 | -0.24 |
| 2024-10-30 | -0.25 |
| 2024-10-29 | -0.24 |
| 2024-10-28 | -0.28 |
| 2024-10-25 | -0.29 |
| 2024-10-24 | -0.24 |
| 2024-10-23 | -0.87 |
| 2024-10-22 | -0.90 |
| 2024-10-21 | -0.93 |
| 2024-10-18 | -0.94 |
| 2024-10-17 | -0.89 |
| 2024-10-16 | -0.92 |
| 2024-10-15 | -0.89 |
| 2024-10-14 | -0.92 |
| 2024-10-11 | -0.90 |
| 2024-10-10 | -0.85 |
| 2024-10-09 | -0.88 |
| 2024-10-08 | -0.89 |
| 2024-10-07 | -0.94 |
| 2024-10-04 | -0.91 |